Hikma Pharmaceuticals PLC (HKMPF)
24.50
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Hikma Pharmaceuticals Enterprise Value: 6.343B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 6.343B |
| May 30, 2024 | 6.343B |
| May 29, 2024 | 6.343B |
| May 28, 2024 | 6.343B |
| May 24, 2024 | 6.343B |
| May 23, 2024 | 6.343B |
| May 22, 2024 | 6.343B |
| May 21, 2024 | 6.343B |
| May 20, 2024 | 6.343B |
| May 17, 2024 | 6.343B |
| May 16, 2024 | 6.343B |
| May 15, 2024 | 6.343B |
| May 14, 2024 | 6.343B |
| May 13, 2024 | 6.343B |
| May 10, 2024 | 6.343B |
| May 09, 2024 | 6.343B |
| May 08, 2024 | 6.343B |
| May 07, 2024 | 6.343B |
| May 06, 2024 | 6.343B |
| May 03, 2024 | 6.343B |
| May 02, 2024 | 5.862B |
| May 01, 2024 | 5.862B |
| April 30, 2024 | 5.862B |
| April 29, 2024 | 5.862B |
| April 26, 2024 | 5.862B |
| Date | Value |
|---|---|
| April 25, 2024 | 5.862B |
| April 24, 2024 | 5.862B |
| April 23, 2024 | 5.862B |
| April 22, 2024 | 5.862B |
| April 19, 2024 | 5.862B |
| April 18, 2024 | 5.862B |
| April 17, 2024 | 5.862B |
| April 16, 2024 | 6.288B |
| April 15, 2024 | 6.288B |
| April 12, 2024 | 6.288B |
| April 11, 2024 | 6.288B |
| April 10, 2024 | 6.288B |
| April 09, 2024 | 6.288B |
| April 08, 2024 | 6.288B |
| April 05, 2024 | 6.288B |
| April 04, 2024 | 6.288B |
| April 03, 2024 | 6.288B |
| April 02, 2024 | 6.288B |
| April 01, 2024 | 6.288B |
| March 28, 2024 | 6.092B |
| March 27, 2024 | 6.092B |
| March 26, 2024 | 6.092B |
| March 25, 2024 | 6.092B |
| March 22, 2024 | 6.092B |
| March 21, 2024 | 6.092B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.120B
Minimum
Sep 23 2022
9.242B
Maximum
Aug 05 2021
6.603B
Average
6.450B
Median
Oct 11 2019
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 142.58M |
| Biodexa Pharmaceuticals Plc | 1.860M |
| Verona Pharma PLC | 772.32M |
| NuCana PLC | -8.064M |
| Autolus Therapeutics PLC | 356.16M |
Enterprise Value Related Metrics
| Earnings Yield | 3.47% |
| Operating Earnings Yield | 11.09% |
| Normalized Earnings Yield | 6.632 |